Sarepta Therapeutics Inc (SRPT): Today's Featured Drugs Laggard

Sarepta Therapeutics ( SRPT) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 0.9%. By the end of trading, Sarepta Therapeutics fell $1.61 (-4.0%) to $38.12 on heavy volume. Throughout the day, 3,343,809 shares of Sarepta Therapeutics exchanged hands as compared to its average daily volume of 1,794,100 shares. The stock ranged in price between $37.25-$39.95 after having opened the day at $39.87 as compared to the previous trading day's close of $39.73. Other companies within the Drugs industry that declined today were: Mast Therapeutics ( MSTX), down 37.2%, Peregrine Pharmaceuticals ( PPHM), down 23.1%, PTC Therapeutics ( PTCT), down 15.1% and Oragenics ( OGEN), down 11.5%.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. Sarepta Therapeutics has a market cap of $1.3 billion and is part of the health care sector. Shares are up 54.0% year to date as of the close of trading on Wednesday. Currently there are 11 analysts that rate Sarepta Therapeutics a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Sarepta Therapeutics as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow and feeble growth in its earnings per share.

On the positive front, ZIOPHARM Oncology ( ZIOP), up 16.2%, Cytokinetics ( CYTK), up 11.1%, Intercept Pharmaceuticals ( ICPT), up 9.8% and Zalicus ( ZLCS), up 9.5% , were all gainers within the drugs industry with Actavis ( ACT) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

null

More from Markets

Lowe's Snags Ex-Home Depot Exec as CEO; ISPs Face Competitive Threat -- ICYMI

Lowe's Snags Ex-Home Depot Exec as CEO; ISPs Face Competitive Threat -- ICYMI

Dow Slips 178 Points; S&P 500 and Nasdaq Also Decline

Dow Slips 178 Points; S&P 500 and Nasdaq Also Decline

Legal Weed Sales in California Are Off to a Less Than Smokin' Start

Legal Weed Sales in California Are Off to a Less Than Smokin' Start

Owner of Moviepass Sees Stock Plummet

Owner of Moviepass Sees Stock Plummet

Ford, GM Gain as China Slashes Auto Import Tariffs

Ford, GM Gain as China Slashes Auto Import Tariffs